首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL-3 |
| Uniprot No | P08700 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-152aa |
| 氨基酸序列 | APMTQTTSLKTSWVNCSNMIDEIITHLKQPPLPLLDFNNLNGEDQDILME NNLRRPNLEAFNRAVKSLQNASAIESILKNLLPCLPLATAAPTRHPIHIK DGDWNEFRRKLTFYLKTLENAQAQQTTLSLAIF |
| 预测分子量 | 15 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-3重组蛋白的3-4篇文献及其摘要的简要概括：
1. **文献名称**：*Production of recombinant human interleukin-3 using a synthetic gene in Escherichia coli*
**作者**：Yang YC, Ciarletta AB, Temple PA, et al.
**摘要**：研究报道了通过合成基因在大肠杆菌中高效表达重组人IL-3的方法，并验证其促进造血祖细胞增殖的活性，为大规模生产奠定基础。
2. **文献名称**：*Binding characteristics and regulation of IL-3 receptors on human hematopoietic cells*
**作者**：Park LS, Friend D, Gillis S, et al.
**摘要**：分析了IL-3重组蛋白与其受体在造血细胞表面的结合机制，揭示了受体亚基的组成及信号转导途径的调控。
3. **文献名称**：*Structure-function analysis of interleukin-3: importance of the C-terminal region for biological activity*
**作者**：Dorssers LC, Burger H, Bot FJ, et al.
**摘要**：通过基因突变实验证明IL-3的C末端结构域对其受体结合和促造血功能的关键作用，为蛋白工程改造提供依据。
4. **文献名称**：*Clinical effects of recombinant human interleukin-3 in patients with chemotherapy-induced cytopenia*
**作者**：Ganser A, Lindemann A, Seipelt G, et al.
**摘要**：临床试验显示，重组IL-3可安全改善化疗后患者的血小板和中性粒细胞减少症，但疗效弱于GM-CSF，提示需联合其他细胞因子。
---
以上文献涵盖IL-3重组蛋白的生产、机制研究、结构功能及临床应用，均为该领域经典或关键研究。实际引用时建议核对具体期刊名称、年份及卷页信息。
Interleukin-3 (IL-3) is a pleiotropic cytokine primarily produced by activated T cells, mast cells, and stromal cells. Discovered in the 1980s, it plays a central role in regulating hematopoiesis by promoting the survival, proliferation, and differentiation of multipotent hematopoietic stem cells and progenitor cells across myeloid lineages. IL-3 binds to a heterodimeric receptor complex consisting of a unique α-chain (IL-3Rα/CD123) and a common β-chain (βc) shared with IL-5 and GM-CSF receptors, triggering JAK-STAT, MAPK, and PI3K signaling pathways.
Recombinant IL-3 protein, typically produced using Escherichia coli or mammalian expression systems, retains the biological activity of native IL-3. Its molecular weight ranges between 15-28 kDa depending on glycosylation patterns. As a research tool, it is widely used to study hematopoiesis mechanisms, expand hematopoietic stem cells in vitro, and investigate immune cell interactions. Clinically, recombinant IL-3 has been explored for treating myelodysplastic syndromes, chemotherapy-induced cytopenia, and bone marrow failure disorders. However, its therapeutic use remains limited compared to other cytokines like G-CSF or erythropoietin, partly due to its broader activity spectrum and potential pro-inflammatory effects.
Current applications focus on combination therapies, particularly in ex vivo cell culture systems for regenerative medicine and immunotherapy. In drug development, IL-3 receptor-targeted therapies (e.g., antibody-drug conjugates against CD123) have gained attention for treating acute myeloid leukemia. Quality-controlled recombinant IL-3 proteins with >95% purity are commercially available, often validated for cell culture and animal studies. Ongoing research continues to explore its role in immune modulation, cancer biology, and platelet production enhancement.
×
